Covid vaccine - opinions?

[the AntiPusher]

Yup, given how you can still catch and transit covid even after vaccination, I'm surprised by that. Most countries have masks mandatory indoors still regardless of vaccination status and I don't see that ending anytime soon either. Are people supposed to dress all in red if they're not vaccinated and green if they are and wear no masks ? Human traffic lights? Class. I should patent that idea. (c) Front242.

You know what is going on here in America..the longer Covid pandemic cases are prevalent the more money the medical and insurance companies are profitable...it's ridiculous when I saw 60 % not wearing masks..as for all the patrons at the MSG basketball game on Thursday..my question is what was the entry criteria?

 

[MargaretMcAleer]

Yup, given how you can still catch and transit covid even after vaccination, I'm surprised by that. Most countries have masks mandatory indoors still regardless of vaccination status and I don't see that ending anytime soon either. Are people supposed to dress all in red if they're not vaccinated and green if they are and wear no masks ? Human traffic lights? Class. I should patent that idea. (c) Front242.

People have to realize that you can still catch COVID even being vaccinated against it.I still wear masks on public transport and shopping malls.In Melbourne they have gone into their 4th lockdown for seven days because of a COVID outbreak,one of the people affected was at a outdoor football match? where thousands of people attended,I do not envy the tracers who have to track those people down.

 

[Front242]

People have to realize that you can still catch COVID even being vaccinated against it.I still wear masks on public transport and shopping malls.In Melbourne they have gone into their 4th lockdown for seven days because of a COVID outbreak,one of the people affected was at a outdoor football match? where thousands of people attended,I do not envy the tracers who have to track those people down.

I admire how diligently they've handled things in Australia and New Zealand. Even one positive covid case and they close everything down. Extreme to many but can't argue with the effectiveness and far better than months and months of lockdowns killing the economy like many other countries. Outdoor transmission is VERY low, 0.1% many claim so unless the person coughed or spluttered on people indoors then fingers crossed no one else will be affected.

 

[MargaretMcAleer]

I admire how diligently they've handled things in Australia and New Zealand. Even one positive covid case and they close everything down. Extreme to many but can't argue with the effectiveness and far better than months and months of lockdowns killing the economy like many other countries. Outdoor transmission is VERY low, 0.1% many claim so unless the person coughed or spluttered on people indoors then fingers crossed no one else will be affected.

At present they are still tracking people,it looks like it will be longer than 7 days.

 

[Carol]

I have vaccinated two days ego and not because I really wanted to do it but if I would travel later its like a second passport, and I have to say that I haven't felt anything, my body has reacted very well, maybe yesterday I felt just a little pain in the arm but only when I raised the arm to reach something but almost nothing, in three weeks i will get the second one

 

[Jelenafan]

I admire how diligently they've handled things in Australia and New Zealand. Even one positive covid case and they close everything down. Extreme to many but can't argue with the effectiveness and far better than months and months of lockdowns killing the economy like many other countries. Outdoor transmission is VERY low, 0.1% many claim so unless the person coughed or spluttered on people indoors then fingers crossed no one else will be affected.

US is landlocked, porous and state-centered government with 50 different protocols for 330 million plus people that for me it’s hard to compare with the aforementioned.

Would the US tolerate the kind of “extreme” complete lockdowns in place in Australia and New Zealand, I wonder.

 

[Front242]

US is landlocked, porous and state-centered government with 50 different protocols for 330 million plus people that for me it’s hard to compare with the aforementioned.

Would the US tolerate the kind of “extreme” complete lockdowns in place in Australia and New Zealand, I wonder.

Completely agree that it's only possible when you're living on an island/not bordering another country but still admire how normal life has been there for over a year now compared to many places. I love working from home but everything else has been bs in much of Europe a long time now.

 

[MargaretMcAleer]

Completely agree that it's only possible when you're living on an island/not bordering another country but still admire how normal life has been there for over a year now compared to many places. I love working from home but everything else has been bs in much of Europe a long time now.

The Australian government introduced 'job keeper' from March last year regarding people whose jobs were put on hold until we got a better grip on COVID.This year in March it was suspended as our work force got back to work,though still people here do work from home.Though it has cost the government millions to put in place Job Keeper.The Victorian government will now apparently compensate the owners of business especially restaurant,cafes and retail who again have to go into lock down for the fourth time

 

[Moxie]

It is important to realize that, while there is still much to be learned, to say, wholesale, that vaccinated people can still get COVID, or spread it, which is true, but is to downplay the effectiveness of the vaccine from spreading it, and in helping to achieve "herd immunity." This is why we get vaccinated, and it's also why we still mask, and observe distancing. I found this helpful:

Can people vaccinated against COVID-19 still spread the coronavirus?

The COVID-19 vaccines are a smash success. But that doesn't mean they keep every vaccinated person completely free of the coronavirus.

www.pbs.org

 

[MargaretMcAleer]

It is important to realize that, while there is still much to be learned, to say, wholesale, that vaccinated people can still get COVID, or spread it, which is true, but is to downplay the effectiveness of the vaccine from spreading it, and in helping to achieve "herd immunity." This is why we get vaccinated, and it's also why we still mask, and observe distancing. I found this helpful:

Can people vaccinated against COVID-19 still spread the coronavirus?

The COVID-19 vaccines are a smash success. But that doesn't mean they keep every vaccinated person completely free of the coronavirus.

www.pbs.org

Thanks,this pandemic is not going away sad to say,it is of the upmost importance that people still wear masks in public places,on transport and shopping malls.,regardless if you are vaccinated.Yes you can still catch COVID if vaccinated,though it wont be as bad if you aren't vaccinated

 

[Moxie]

Thanks,this pandemic is not going away sad to say,it is of the upmost importance that people still wear masks in public places,on transport and shopping malls.,regardless if you are vaccinated.Yes you can still catch COVID if vaccinated,though it wont be as bad if you aren't vaccinated

And you are much less likely to spread it. I wanted to dig into the fine points, because, on the RG men's thread, it was being hit too hard, IMO, that you can still get it, or spread it, even if vaccinated. But there is real evidence that that is lessened with vaccination. We'll know more over time, but the smart money says: get the vaccine, but continue to observe protocols like mask-wearing and social distancing. We're at a much more normal place than we were a year ago, but we are far from "normal," and this thing is far from over.

 

[MargaretMcAleer]

And you are much less likely to spread it. I wanted to dig into the fine points, because, on the RG men's thread, it was being hit too hard, IMO, that you can still get it, or spread it, even if vaccinated. But there is real evidence that that is lessened with vaccination. We'll know more over time, but the smart money says: get the vaccine, but continue to observe protocols like mask-wearing and social distancing. We're at a much more normal place than we were a year ago, but we are far from "normal," and this thing is far from over.

Of course it is lessened with vaccination,still we need to adhere with the protocols of mask wearing and social distancing.I just hope people do not think it is over with getting a vaccine because that is not the case.Yes things have returned a bit to normality,still we have to be aware at all times.

 

[Moxie]

Of course it is lessened with vaccination,still we need to adhere with the protocols of mask wearing and social distancing.I just hope people do not think it is over with getting a vaccine because that is not the case.Yes things have returned a bit to normality,still we have to be aware at all times.

I have to say, here in NYC, where we have had very strict protocols, and people have adhered to them, there is a bit of a "whoo-hoo!" since the vaccine and the relaxing of outdoor mask mandates. And I'm currently working on a job that shoots in both LA and NY, and I have come to realize just how different attitudes are in LA vs. NY. LA is much more relaxed than we are, though, in my business, (film,) we do observe all protocols when working together. And pretesting is mandatory. We pay for it, and test everyone w/in 3 days of working together. Crews are limited, and we can only have so many people in a space at one time. And it works. There have been very few outbreaks or shutdowns of production in my business, and given the freelance nature of the business, we are potential super-spreaders. So strict protocols do work, and they got us back working as of last June.

 

[MargaretMcAleer]

I have to say, here in NYC, where we have had very strict protocols, and people have adhered to them, there is a bit of a "whoo-hoo!" since the vaccine and the relaxing of outdoor mask mandates. And I'm currently working on a job that shoots in both LA and NY, and I have come to realize just how different attitudes are in LA vs. NY. LA is much more relaxed than we are, though, in my business, (film,) we do observe all protocols when working together. And pretesting is mandatory. We pay for it, and test everyone w/in 3 days of working together. Crews are limited, and we can only have so many people in a space at one time. And it works. There have been very few outbreaks or shutdowns of production in my business, and given the freelance nature of the business, we are potential super-spreaders. So strict protocols do work, and they got us back working as of last June.

Really great to hear,I wish everyone would take on those protocols,and stick to them.

 

[Vince Evert]

Margeret , did you see this in the channel 9 news last week? Now these patches could potentially be a game-changer because lets face it, there are always going to be folks who for one reason or another, are absolutely against needles, that's just the reality.

Vaccines delivered via a painless, throw-away patch could one day eliminate the need for needle-and-syringe flu injections, researchers have revealed after completing a preliminary trial.
Equipped with micro-needles, the patches vaccinated against influenza just as effectively as a standard flu jab, researchers reported in the medical journal The Lancet.
“This bandage-strip sized patch of dissolvable needles can transform how we get vaccinated,” said Roderic Pettigrew, director of the US National Institute of Biomedical Imaging and Bioengineering, which funded the study.

A hundred tiny needles - just long enough to penetrate the skin - embedded in each patch dissolve within minutes when exposed to moisture from the body.

Adhesive holds the patch close the skin while the vaccine is released, and can be peeled away after 20 minutes and discarded.
Professor Robert Booy, of the Westmead Institute of Medical Research, has said the patch is still “three to four years” away from hitting the market, but called it “game changing”.
“It’s very exciting to have a means of giving vaccines that protects people, that’s safe and they can do it themselves,” he said.
“This work is really important, it’s changing the game.”

Mr Booy said a team in Queensland is also researching a flu patch.
“The work in Queensland is competing with the work from the US and the two groups are both doing great work,” he said.

“The Australian work has the advantage of being local and therefore able to supply the local market.”
He noted however the Australian team is working on a non-dissolving patch.
“It may be more immunogenic,” he added.
The new technology can be self-administered and stored without refrigeration, making it significantly cheaper than traditional vaccines.

In phase one clinical trials, researchers from Emory University in Georgia and the Georgia Institute of Technology randomly divided 100 adults into four groups.
Three received the micro-needle patches: one delivered by a healthcare provider; one self-administered; and the third - delivered by a nurse - a placebo without any active ingredients.
The fourth group received a classic flu jab with a syringe.


All the active flu vaccines worked equally well for at least six months, regardless of whether they were delivered by professionals or the patient, or whether they were administered by a syringe or a micro-needle.
The manufacturing cost for the patches is expected to be about the same as for pre-filled syringes.
But the patch is expected to be cheaper because it can be sent through the mail and self-administered.
In addition, it is stable for a year at 40 degrees Celsius (104 degrees Fahrenheit), and does not require refrigeration, the researchers said.
“These advantages could reduce the cost of the flu vaccine and potentially increase coverage,” said lead author Nadine Rouphael, an associate professor at Emory. “Our findings now need confirming in larger trials.”

Mark Prausnitz, a professor at the Georgia Institute of Technology, led the design of the small coin-sized patch, and is co-founder of a company that is licensing the technology.
Mr Booy said when the patch hits the market it will likely have a significant impact on the number of people getting vaccinated.

“There is a big minority of people who won’t have vaccinations in general because of needles,” he said, adding that the patch design could be applied to other forms of vaccinations.
“A product like this would boost not only flu vaccinations but it (could) apply to other diseases – could be a real boom,” he said.
“A number of diseases are being investigated for the use of these skin patches, not just influenza.
“It could easily be rolled out to children, be more palatable for children”

Now here's the video link, hope it plays outside of AU.https://www.9news.com.au/world/pain...ab-study/4105ecb5-4584-40fa-99bb-3581ddeefa76

 

[Vince Evert]

These drugs are under clinical trial:

Researchers discover drug that blocks multiple SARS-CoV-2 variants in mice -

The drug diABZI -- which activates the body's innate immune response -- was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2, according to scientists in the Perelman School of Medicine at the University of Pennsylvania. The findings, published this month in Science Immunology, suggest that diABZI could also treat other respiratory coronaviruses.

"Few drugs have been identified as game-changers in blocking SARS-CoV-2 infection. This paper is the first to show that activating an early immune response therapeutically with a single dose is a promising strategy for controlling the virus, including the South African variant B.1.351, which has led to worldwide concern," said senior author Sara Cherry, PhD, a professor of Pathology and Laboratory Medicine and scientific director of the High-Throughput Screening (HTS) Core at Penn Medicine. "The development of effective antivirals is urgently needed for controlling SARS-CoV-2 infection and disease, especially as dangerous variants of the virus continue to emerge."

The SARS-CoV-2 virus initially targets epithelial cells in the respiratory tract. As the first line of defense against infection, the respiratory tract's innate immune system recognizes viral pathogens by detecting their molecular patterns. Cherry and her research team first sought to better understand this effect by observing human lung cell lines under the microscope that had been infected with SARS-CoV-2. They found that the virus is able to hide, delaying the immune system's early recognition and response. The researchers predicted that they may be able to identify drugs -- or small molecules with drug-like properties -- that could set off this immune response in the respiratory cells earlier and prevent severe SARS-CoV-2 infection.

To identify antiviral agonists that would block SARS-CoV-2 infection, the researchers performed high throughput screening of 75 drugs that target sensing pathways in lung cells. They examined their effects on viral infection under microscopy and identified nine candidates -- including two cyclic dinucleotides (CDNs) -- that significantly suppressed infection by activating STING (the simulation of interferon genes).

Since CDNs have low potency and make poor drugs, according to Cherry, she and her team decided to also test a newly-developed small molecule STING agonist called diABZI, which is not approved by the Food and Drug Administration but is currently being tested in clinical trials to treat some cancers. The researchers found that diABZI potently inhibits SARS-CoV-2 infection of diverse strains, including variant of concern B.1.351, by stimulating interferon signaling.

Finally, the researchers tested the effectiveness of diABZI in transgenic mice that had been infected with SARS-CoV-2. Because the drug needed to reach the lungs, diABZI was administered through a nasal delivery. diABZI-treated mice showed much less weight loss than the control mice, had significantly-reduced viral loads in their lungs and nostrils, and increased cytokine production -- all supporting the finding that diABZI stimulates interferon for protective immunity.

Cherry said that the study's findings offer promise that diABZI could be an effective treatment for SARS-CoV-2 that could prevent severe COVID-19 symptoms and the spread of infection. Additionally, since diABZI has been shown to inhibit human parainfluenza virus and rhinovirus replication in cultured cells, the STING agonist may be more broadly effective against other respiratory viruses.

"We are now testing this STING agonist against many other viruses," Cherry said. "It's really important to remember that SARS-CoV-2 is not going to be the last coronavirus that we will see and will need protection against."

Researchers discover drug that blocks multiple SARS-CoV-2 variants in mice

A small molecule STING agonist was highly protective against the virus that causes COVID-19 and likely other coronaviruses, researchers have found.

www.sciencedaily.com

 

[Vince Evert]

and there's this !

Queensland scientists develop peptide-based drugs that could reduce severity of COVID-19



Queensland,AU scientists have developed two new drugs that could prevent COVID-19 infection and stop further spread of the virus in patients who have already contracted it.

The research team at QIMR Berghofer has come up with two separate peptide-based drugs that could be available to patients within 18 months if trials are successful.

The drugs target the human cells' response to the SARS-CoV-2 virus instead of the virus itself.

The findings of their research were published overnight in the journal Nature Cell Discovery.


Senior Researcher at QIMR Berghofer, Professor Sudha Rao, said the first drug is designed to prevent infection and would be administered pre-exposure and aid the efficacy of vaccines, while the second drug would prevent the spread of the virus within cells.

"The first treatment works by blocking the virus from entering as it effectively acts like a padlock on the human cells," she said.

"And the second drug, if the virus does enter, it prevents the virus from replicating.

"They are really what we call early intervention drugs, so they really are there to reduce the severity of the disease."

The development of the drugs came after researchers uncovered a previously unknown way that SARS-CoV-2 entered cells and cause COVID-19.

"We know that the ACE2 receptor is the critical entry point as to how the virus enters," Professor Rao said.

"What we've really uncovered is the way the virus is able to exploit the human cells and allow the ACE2 door to become fully open, and therefore the virus can rapidly enter.

"Once it enters it can use the cellular machinery in the human cells to replicate.

"And knowing that … one drug really acts like a cloak around the human cell and therefore prevents the virus from entering through the ACE2 receptor.

"Whereas the second drug … if the virus does enter, the drug is specifically there to prevent the virus from replicating."

Infectious diseases expert, Dr Paul Griffin said it was very exciting and a big step forward but a lot more work needed to be done.

"This — whilst very promising — sounds to be very early in the journey of these potential candidate drugs and obviously a lot more work needs to happen before we know that they're safe and effective in humans and do what we hope they will do," Dr Griffin said.

Dr Griffin believes the new drugs could be a great long-term solution and incredibly useful in limiting the impact of the virus, in addition to the vaccine rollout.

"In many ways, it's clear while a vaccine is a huge part of our strategy, therapies to prevent people getting really sick ... will be really helpful and certainly aid what the vaccine is able to do if we can get therapies that can do those sorts of things.

"We know we're not going to be able to protect 100 per cent of people, 100 per cent of the time with vaccines and so it's very likely that there'll be people in our population that remain susceptible to this infection and it'll keep circulating … so if we can do something to make them less likely to get unwell or infect others that will be a huge step forward."
'We're hoping to start clinical trials in a few months'

Laboratory tests have demonstrated that if the virus does infect a cell, the second drug is able to prevent the virus from "hijacking" the host cell and replicating.

This boosts the immune system's ability to recognise the virus.

Professor Rao said the results of the laboratory testing were "looking very promising".

"All our testing has been done in human cells and in gold-standard models of the SARS-CoV-2 virus, the COVID-19 models and in both of those what we've been able to show is that [these] drugs are very safe.

"We're waiting on final results, because we are wanting to go very soon into human testing.

"We're really hoping to start the drugs would be effective against all variants of the virus.

"The way that these drugs have been designed, they will be able to block all variants, all these betacoronaviruses," Professor Rao said.

"We have developed the drug against the region which is conserved amongst all the variants.

"So, it will be as effective against the variants as well."

Although Queensland scientists are leading the research, it is an international collaboration.

"Even though we're leading this, we're part of an international consortium, and we are working with leaders in infectious diseases in Europe, where the COVID-19 disease is very rife … so there's lots of patients," Professor Rao said.

"So it means that not only can we start the clinical trial, you want to be able to complete the clinical trial rapidly, so you can get it to as many people as possible."


https://www.abc.net.au/news/2021-05...s-could-reduce-severity-of-covid-19/100162184

 

[MargaretMcAleer]

Margeret , did you see this in the channel 9 news last week? Now these patches could potentially be a game-changer because lets face it, there are always going to be folks who for one reason or another, are absolutely against needles, that's just the reality.

Vaccines delivered via a painless, throw-away patch could one day eliminate the need for needle-and-syringe flu injections, researchers have revealed after completing a preliminary trial.
Equipped with micro-needles, the patches vaccinated against influenza just as effectively as a standard flu jab, researchers reported in the medical journal The Lancet.
“This bandage-strip sized patch of dissolvable needles can transform how we get vaccinated,” said Roderic Pettigrew, director of the US National Institute of Biomedical Imaging and Bioengineering, which funded the study.

A hundred tiny needles - just long enough to penetrate the skin - embedded in each patch dissolve within minutes when exposed to moisture from the body.

Adhesive holds the patch close the skin while the vaccine is released, and can be peeled away after 20 minutes and discarded.
Professor Robert Booy, of the Westmead Institute of Medical Research, has said the patch is still “three to four years” away from hitting the market, but called it “game changing”.
“It’s very exciting to have a means of giving vaccines that protects people, that’s safe and they can do it themselves,” he said.
“This work is really important, it’s changing the game.”

Mr Booy said a team in Queensland is also researching a flu patch.
“The work in Queensland is competing with the work from the US and the two groups are both doing great work,” he said.

“The Australian work has the advantage of being local and therefore able to supply the local market.”
He noted however the Australian team is working on a non-dissolving patch.
“It may be more immunogenic,” he added.
The new technology can be self-administered and stored without refrigeration, making it significantly cheaper than traditional vaccines.

In phase one clinical trials, researchers from Emory University in Georgia and the Georgia Institute of Technology randomly divided 100 adults into four groups.
Three received the micro-needle patches: one delivered by a healthcare provider; one self-administered; and the third - delivered by a nurse - a placebo without any active ingredients.
The fourth group received a classic flu jab with a syringe.


All the active flu vaccines worked equally well for at least six months, regardless of whether they were delivered by professionals or the patient, or whether they were administered by a syringe or a micro-needle.
The manufacturing cost for the patches is expected to be about the same as for pre-filled syringes.
But the patch is expected to be cheaper because it can be sent through the mail and self-administered.
In addition, it is stable for a year at 40 degrees Celsius (104 degrees Fahrenheit), and does not require refrigeration, the researchers said.
“These advantages could reduce the cost of the flu vaccine and potentially increase coverage,” said lead author Nadine Rouphael, an associate professor at Emory. “Our findings now need confirming in larger trials.”

Mark Prausnitz, a professor at the Georgia Institute of Technology, led the design of the small coin-sized patch, and is co-founder of a company that is licensing the technology.
Mr Booy said when the patch hits the market it will likely have a significant impact on the number of people getting vaccinated.

“There is a big minority of people who won’t have vaccinations in general because of needles,” he said, adding that the patch design could be applied to other forms of vaccinations.
“A product like this would boost not only flu vaccinations but it (could) apply to other diseases – could be a real boom,” he said.
“A number of diseases are being investigated for the use of these skin patches, not just influenza.
“It could easily be rolled out to children, be more palatable for children”

Now here's the video link, hope it plays outside of AU.https://www.9news.com.au/world/pain...ab-study/4105ecb5-4584-40fa-99bb-3581ddeefa76

Margeret , did you see this in the channel 9 news last week? Now these patches could potentially be a game-changer because lets face it, there are always going to be folks who for one reason or another, are absolutely against needles, that's just the reality.

Vaccines delivered via a painless, throw-away patch could one day eliminate the need for needle-and-syringe flu injections, researchers have revealed after completing a preliminary trial.
Equipped with micro-needles, the patches vaccinated against influenza just as effectively as a standard flu jab, researchers reported in the medical journal The Lancet.
“This bandage-strip sized patch of dissolvable needles can transform how we get vaccinated,” said Roderic Pettigrew, director of the US National Institute of Biomedical Imaging and Bioengineering, which funded the study.

A hundred tiny needles - just long enough to penetrate the skin - embedded in each patch dissolve within minutes when exposed to moisture from the body.

Adhesive holds the patch close the skin while the vaccine is released, and can be peeled away after 20 minutes and discarded.
Professor Robert Booy, of the Westmead Institute of Medical Research, has said the patch is still “three to four years” away from hitting the market, but called it “game changing”.
“It’s very exciting to have a means of giving vaccines that protects people, that’s safe and they can do it themselves,” he said.
“This work is really important, it’s changing the game.”

Mr Booy said a team in Queensland is also researching a flu patch.
“The work in Queensland is competing with the work from the US and the two groups are both doing great work,” he said.

“The Australian work has the advantage of being local and therefore able to supply the local market.”
He noted however the Australian team is working on a non-dissolving patch.
“It may be more immunogenic,” he added.
The new technology can be self-administered and stored without refrigeration, making it significantly cheaper than traditional vaccines.

In phase one clinical trials, researchers from Emory University in Georgia and the Georgia Institute of Technology randomly divided 100 adults into four groups.
Three received the micro-needle patches: one delivered by a healthcare provider; one self-administered; and the third - delivered by a nurse - a placebo without any active ingredients.
The fourth group received a classic flu jab with a syringe.


All the active flu vaccines worked equally well for at least six months, regardless of whether they were delivered by professionals or the patient, or whether they were administered by a syringe or a micro-needle.
The manufacturing cost for the patches is expected to be about the same as for pre-filled syringes.
But the patch is expected to be cheaper because it can be sent through the mail and self-administered.
In addition, it is stable for a year at 40 degrees Celsius (104 degrees Fahrenheit), and does not require refrigeration, the researchers said.
“These advantages could reduce the cost of the flu vaccine and potentially increase coverage,” said lead author Nadine Rouphael, an associate professor at Emory. “Our findings now need confirming in larger trials.”

Mark Prausnitz, a professor at the Georgia Institute of Technology, led the design of the small coin-sized patch, and is co-founder of a company that is licensing the technology.
Mr Booy said when the patch hits the market it will likely have a significant impact on the number of people getting vaccinated.

“There is a big minority of people who won’t have vaccinations in general because of needles,” he said, adding that the patch design could be applied to other forms of vaccinations.
“A product like this would boost not only flu vaccinations but it (could) apply to other diseases – could be a real boom,” he said.
“A number of diseases are being investigated for the use of these skin patches, not just influenza.
“It could easily be rolled out to children, be more palatable for children”

Now here's the video link, hope it plays outside of AU.https://www.9news.com.au/world/pain...ab-study/4105ecb5-4584-40fa-99bb-3581ddeefa76

Thanks I did see that on the news,thanks for the link.Queenslanders have been the forefront in research for sometime now

 

[Vince Evert]

Big talk right now is the hotel quarantining in each state is not adequate. Longer term Post-covid facilites are needed but where's the money needed to fund these, going to come from?.

Quarantine overhaul call after SA medi-hotel breach​

Quarantine overhaul call after SA medi-hotel breach - InDaily

indaily.com.au

 

[the AntiPusher]

Front did you take the vaccine? I couldn't read though all of those Previously written posts...I'm I recall you are anti-vaccine .. is that correct

I took both Pfizer's vaccine vaccination shots.(first shot late February..first responder qualified)